[Clinical studies on T-2588 in the field of otorhinolaryngology].
From clinical studies on T-2588, an oral ester type cephem, the following results were obtained. Ten patients with acute tonsillitis, 3 with acute pharyngolaryngitis, 2 with acute sinusitis, 1 with acute exacerbation of chronic sinusitis and 2 with acute exacerbation of chronic otitis media were treated with T-2588 at a daily dose of 300 or 600 mg. Clinical responses were excellent in 12, good in 4, fair in 1 and poor in 1. Clinical efficacy was 88.9%. Bacteriologically, all isolates except one strain of S. aureus were eliminated. Clinical efficacies classified by clinical isolates correlated well with bacteriological efficacies. The MICs of T-2525 against clinical isolates were determined and compared with those of cephalexin, cefaclor and amoxicillin. The T-2525 showed potent antibacterial activity against Gram-positive and Gram-negative bacteria including S. pneumoniae, H. influenzae and beta-Streptococcus, but the activity of T-2525 against S. aureus was similar to that of the other antibiotics examined. Neither side effect nor abnormal laboratory finding was observed.
D000284:Administration, Oral; D000328:Adult; D015281:Cefmenoxime / Q000031:analogs & derivatives*; D002511:Cephalosporins / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007827:Laryngitis / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010612:Pharyngitis / Q000188:drug therapy*; D012852:Sinusitis / Q000188:drug therapy; D014069:Tonsillitis / Q000188:drug therapy*
D002511:Cephalosporins; C046817:cefteram pivoxil; D015281:Cefmenoxime